Dianthus Therapeutics, Inc. (DNTH) revenue and earnings history
Dianthus Therapeutics, Inc. reported revenue of $2.04M for fiscal 2025 (year ended Dec 31, 2025), −67.3% on the year before, and net income of −$162M.
Revenue and net income, 10 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $2.04M−67.3% | −$178M | −$162M | −$129M | — | — | $22.8M | — | — | $51.1M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Dianthus Therapeutics, Inc. (DNTH) on OQRO.
Common questions
What was Dianthus Therapeutics, Inc.'s revenue in fiscal 2025?
$2.04M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 9, 2026. That is −67.3% on fiscal 2024 ($6.24M).
Has Dianthus Therapeutics, Inc. been profitable?
It reported a net loss in 10 of the years shown (2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$9.43M in fiscal 2016.
Does Dianthus Therapeutics, Inc. buy back shares or pay dividends?
None of the 10 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Why is earnings per share not in this table?
Where these figures come from
The SEC’s companyfacts data: every figure Dianthus Therapeutics, Inc. tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
